Home > Result Summaries: Compounds > Combined Measles, Mumps, Rubella, Varicella Vaccine > Result Summary for 106670

Result Summary for 106670

Result Summary

Protocol ID:	106670
Clinical Study ID:	106670
Official Title:	Open, multicenter, randomised, controlled phase IIIb study evaluating the immunogenicity and safety of subcutaneous versus alternative administration route of combined MeMuRu-OKA vaccine to healthy children aged 11 to 21 months.
Phase:	Phase 3
Study Indications or Diseases:	Measles-Mumps-Rubella-Varicella Vaccine
Generic Name:	Combined Measles, Mumps, Rubella, Varicella Vaccine
Trade/Product Name:	Priorix-Tetra
Approved Drug Label:	http://www.gsk.com/products.html
Results Summary:	Click here to download result summary.
Citations:	Knuf M et al. Safety, tolerability and immediate pain after subcutaneous versus intramuscular administration of a measles-mumps-rubella-varicella 5MMRV) vaccine to children aged 11-21 months. Abstract presented at the 26th Annual Meeting of the European Society for Paediatric Infectious Diseases (ESPID), Graz, Austria, 13-17 May 2008.